Stock Taper 
OKYO
$1.67
▲ UP 7.74% (0.12)
KEY STATISTICS
Market Cap$64.07 M
52w High$3.20
52w Low$1.34
Dividend Yield—
Frequency—
P/E-33.27
Volume135.39K
Shares Out.38.37M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Robert J. Dempsey
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 17, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
5
PRICE TARGET
Target High$5.00
Target Low$5.00
Target Median$5.00
Target Consensus$5.00
UPCOMING EARNINGS
DateDec 2, 2026
DayWednesday
Rev. Est.—
DEC
2
WED
PRICE
$1.67 ▲ UP 7.74% (+$0.12)About OKYO Pharma Limited
https://www.okyopharma.com ↗OKYO Pharma Limited, a UK-based preclinical biopharmaceutical company founded in 2007, develops therapeutics like OK-101 for dry eye and OK-201 for neuropathic ocular pain.
INDUSTRY
Biotechnology
A PRODUCT OKYO PHARMA LIMITED IS KNOWN FOR
Urcosimod (OK-101)
Urcosimod, OKYO Pharma's lead drug candidate in Phase 2 for neuropathic corneal pain and dry eye disease, has FDA Fast Track designation, highlighting its potential to treat inflammatory eye conditions.
RATINGS SNAPSHOT
Overall rating: C-
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1
INSIDER TRADES
★
DIRECTOR, 10 PERCENT OWNER:
CERRONE GABRIELE M
Purchase · 25.0K shares
2026-07-20
★
OFFICER: CHIEF MEDICAL OFFICER
Mantelli Flavio
Purchase · 20.0K shares
2026-07-21
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Patil Rajkumar V.
Purchase · 3.4K shares
2026-07-27
★
DIRECTOR
BRANCACCIO JOHN P
Purchase · 5.0K shares
2026-07-21
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 IMMX | $13.94 | COMPARE |
 ZNTL | $3.80 | COMPARE |
 WHWK | $4.62 | COMPARE |
 MGNX | $4.13 | COMPARE |
 SLGL | $68.81 | COMPARE |
 COYA | $4.59 | COMPARE |
 PLRX | $1.11 | COMPARE |
 TLSA | $1.01 | COMPARE |